Genitourinary syndrome of menopause – Is the problem solved? State of the art 2018

Jacek Szymański, Kornelia Zaręba, Grzegorz Jakiel, Aneta Słabuszewska-Jóźwiak

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Vulvovaginal atrophy accompanied by lower urinary tract dysfunction related to low levels of estrogen and androgens is labeled as genitourinary syndrome of menopause (GSM). Although this condition affects most postmenopausal women worldwide, it seems to be underdiagnosed and undertreated. Women should be properly advised to choose an adequate treatment modality to improve their quality of life, sexual relationships and social activity. The aim of this article to is increase knowledge of GSM. The current treatment options, both hormonal and non-hormonal, are reviewed. Topical estrogen therapy still remains the gold standard, but the demand for individually tailored therapy is growing. New treatment modalities are continuously included in clinical practice. They should consider the whole personality of a woman as well as cultural and social factors. Further studies on GSM and on the effectiveness of various treatment options are necessary to achieve this purpose.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalPrzeglad Menopauzalny
Issue number4
Publication statusPublished - 2018
Externally publishedYes


  • Androgens
  • Estrogens
  • Laser
  • Menopause
  • RF devices.
  • SERMs
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology


Dive into the research topics of 'Genitourinary syndrome of menopause – Is the problem solved? State of the art 2018'. Together they form a unique fingerprint.

Cite this